海外の治験の状況「1」での検索結果
10032件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- Evaluation of Behavioural Therapy as a First Line Treatment in Noctural Polyuria. A Single Centre Interventional Prospective Study.
- Nocturnal Polyuria (as a cause of nocturia) Nocturia, Asian Population, Nocturnal Polyuria in elderly men, Non-pharmacological therapy,;Nocturia, Asian Population, Nocturnal Polyuria in elderly men, Non-pharmacological therapy,
- Malaysia
- 2019-06-08
Recruiting
- Study of Volitinib in advanced gastric adenocarcinoma patients with MET amplification as third-line treatment
- ;Neoplasms
- Korea, Republic of
- 2019-06-19
Not Recruiting
- Study for the efficacy and tolerance of metronome chemotherapy combined with a generation of egfr-tki in first-line treatment of advanced egfr-positive NSCLC
- Lung adenocarcinoma with EGFR mutation
- China
- 2019-06-22
Not Recruiting
- A prospective, single-center, single-arm clinical observational study for anlotinib in the treatment of second-line and above chemotherapy failed recurrent and/or metastatic head and neck squamous cell carcinoma
- Recurrent and/or metastatic head and neck squamous cell carcinoma
- China
- 2019-06-22
Recruiting
- Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
- Non Small Cell Lung Cancer
- China
- 2019-07-21
Not Recruiting
- HLA haploidentical hematopoietic stem cell transplantation as a first-line treatment for acute aplastic anemia: a multicenter controlled study
- Acute aplastic anemia
- China
- 2019-07-20
Recruiting
- A Study to Evaluate Carelizumab in Combination With Capecitabine and Apatinib as Second-Line Therapy in Treatment of Advanced Gastric Cancer
- Gatric cancer
- China
- 2019-07-15
Recruiting
- Clinical study of Anlotinib as Third-Line or Further Treatment on Advanced Epithelial Ovarian Cancer
- epithelial ovarian cancer
- China
- 2019-07-05
Not recruiting
- Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
- Metastatic Colorectal Cancer
- China
- 2019-07-02
Not Recruiting
- A randomized, double-blind, parallel controlled trial for Icotinib double-dose first-line therapy for EGFR 21 exon mutations in advanced non-small cell lung cancer
- Non-small cell lung cancer
- China
- 2019-08-17
Recruiting
- First Line Therapy for High Risk Acute GVHD
- aGVHD;Stem Cell Transplant Complications
- China
- 2019-08-17
Not Recruiting
- Study for Determaination of Carelizumab in Combination With Nab-paclitaxe and Apatinib as Second-Line Therapy in the Treatment of HER2-negtive Advanced Gastric Cancer
- Gatric cancer
- China
- 2019-08-10
Recruiting
- Nab-paclitaxel plus capecitabine as first-line treatment of recurrent/metastatic cholangi ocarcinoma: a multi-center, open label, single-arm study
- recurrent/metastatic cholangiocarcinoma
- China
- 2019-08-06
Recruiting
- Study of KN046 With Chemotherapy in First Line Advanced NSCLC
- Non-small Cell Lung Cancer
- China
- 2019-08-06
Not Recruiting
- Phase II Clinical Trail of Anlotinib Combined with Sintilimab in the Second-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer.
- Non-Small Cell Lung Cancer
- China
- 2019-09-04
Recruiting
- Phase II clinical study for Camrelizumab combined with Albumin Paclitaxe and Carboplatin in the first-line treatment of advanced non-small cell lung cancer
- advanced non-small cell lung cancer
- China
- 2019-09-29
Not Recruiting
- mXELOXIRI versus FOLFOX/FOLFIRI Combined With Molecular Targeting Drug in the First-line Treatment of Patients With Initially Unresectable Metastatic Colorectal Cancer: A Phase II, Randomized, Prospective Controlled Trial
- Initially Unresectable Metastatic Colorectal Cancer
- China
- 2019-10-13
Not Recruiting
- Phase II clinical study for Sintilimab in the maintenance therapy after first-line chemotherapy of advanced lung squamous cell carcinoma
- Lung cancer
- China
- 2019-10-10
Recruiting
- A real-world study for the efficacy and influencing factors of pemetrexed combined with EGFR-TKIs in the first-line treatment of advanced NSCLC patients
- Lung adenocarcinoma
- China
- 2019-10-09
Not Recruiting
- A prospective, single-arm, exploratory study for Camrelizumab combined with TP chemotherapy for first-line treatment in patients with recurrent/metastatic or locally advanced inoperable oral squamous cell carcinoma
- oral squamous cell carcinoma
- China
- 2019-10-20